TY - JOUR AU - Rouleau, Jean TI - Decreasing the Risk of Heart Failure in a Changing Post-Myocardial Infarction Environment JF - NEW ENGLAND JOURNAL OF MEDICINE J2 - NEW ENGL J MED PY - 2024 PG - 2 SN - 0028-4793 DO - 10.1056/NEJMe2402719 UR - https://m2.mtmt.hu/api/publication/34804716 ID - 34804716 AB - A number of therapies that have been shown to be effective in patients with chronic heart failure, including beta-blockers, mineralocorticoid receptor antagonists, and renin-angiotensin system inhibitors, have also been shown to be beneficial in patients with evidence of left ventricular systolic dysfunction, pulmonary congestion, or both after an acute myocardial infarction.(1) However, the effectiveness of an agent in patients with chronic heart failure does not necessarily imply that the agent will be effective in patients who have had an acute myocardial infarction. For example, despite the effectiveness of sacubitril-valsartan in decreasing the risk of death from cardiovascular causes or hospitalization . . . LA - English DB - MTMT ER - TY - JOUR AU - Ballantyne, Christie M. AU - Nambi, Vijay TI - HDL Therapeutics - Time for a Curtain Call or Time to Reconceptualize? JF - NEW ENGLAND JOURNAL OF MEDICINE J2 - NEW ENGL J MED PY - 2024 PG - 2 SN - 0028-4793 DO - 10.1056/NEJMe2403036 UR - https://m2.mtmt.hu/api/publication/34804386 ID - 34804386 AB - The identification of an inverse association between high-density lipoprotein (HDL) cholesterol levels and incident cardiovascular disease events,(1) combined with research on the role of HDL in reverse cholesterol transport, led to the exploration of therapies directed toward increasing HDL cholesterol. However, although therapies such as cholesteryl-ester transfer protein inhibitors increased HDL cholesterol levels, these therapies did not reduce the incidence of cardiovascular disease events.(1,2) Consequently, the focus of HDL therapeutics shifted to attempting to improve the functionality, or quality, of HDL, and efforts to measure and enhance cholesterol efflux capacity and thereby promote reverse cholesterol transport were initiated.(1,2) Although the . . . LA - English DB - MTMT ER - TY - JOUR AU - Butler, Javed AU - Jones, W. Schuyler AU - Udell, Jacob A. AU - Anker, Stefan D. AU - Petrie, Mark C. AU - Harrington, Josephine AU - Mattheus, Michaela AU - Zwiener, Isabella AU - Amir, Offer AU - Bahit, M. Cecilia AU - Bauersachs, Johann AU - Bayes-Genis, Antoni AU - Chen, Yundai AU - Chopra, Vijay K. AU - Figtree, Gemma AU - Ge, Junbo AU - Goodman, Shaun G. AU - Gotcheva, Nina AU - Goto, Shinya AU - Gasior, Tomasz AU - Jamal, Waheed AU - Januzzi, James L. AU - Jeong, Myung Ho AU - Lopatin, Yuri AU - Lopes, Renato D. AU - Merkely, Béla Péter AU - Parikh, Puja B. AU - Parkhomenko, Alexander AU - Ponikowski, Piotr AU - Rossello, Xavier AU - Schou, Morten AU - Simic, Dragan AU - Steg, P. Gabriel AU - Szachniewicz, Joanna AU - van der Meer, Peter AU - Vinereanu, Dragos AU - Zieroth, Shelley AU - Brueckmann, Martina AU - Sumin, Mikhail AU - Bhatt, Deepak L. AU - Hernandez, Adrian F. TI - Empagliflozin after Acute Myocardial Infarction JF - NEW ENGLAND JOURNAL OF MEDICINE J2 - NEW ENGL J MED VL - In press PY - 2024 SP - In press SN - 0028-4793 DO - 10.1056/NEJMoa2314051 UR - https://m2.mtmt.hu/api/publication/34801043 ID - 34801043 LA - English DB - MTMT ER - TY - JOUR AU - Gibson, C. Michael AU - Duffy, Danielle AU - Korjian, Serge AU - Bahit, M. Cecilia AU - Chi, Gerald AU - Alexander, John H. AU - Lincoff, A. Michael AU - Heise, Mark AU - Tricoci, Pierluigi AU - Deckelbaum, Lawrence I. AU - Mears, Sojaita Jenny AU - Nicolau, Jose C. AU - Lopes, Renato D. AU - Merkely, Béla Péter AU - Lewis, Basil S. AU - Cornel, Jan H. AU - Trebacz, Jaroslaw AU - Parkhomenko, Alexander AU - Libby, Peter AU - Sacks, Frank M. AU - Povsic, Thomas J. AU - Bonaca, Marc AU - Goodman, Shaun G. AU - Bhatt, Deepak L. AU - Tendera, Michal AU - Steg, P. Gabriel AU - Ridker, Paul M. AU - Aylward, Philip AU - Kastelein, John J. P. AU - Bode, Christoph AU - Mahaffey, Kenneth W. AU - Nicholls, Stephen J. AU - Pocock, Stuart J. AU - Mehran, Roxana AU - Harrington, Robert A. TI - Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction JF - NEW ENGLAND JOURNAL OF MEDICINE J2 - NEW ENGL J MED PY - 2024 PG - 11 SN - 0028-4793 DO - 10.1056/NEJMoa2400969 UR - https://m2.mtmt.hu/api/publication/34799254 ID - 34799254 AB - Background Cardiovascular events frequently recur after acute myocardial infarction, and low cholesterol efflux - a process mediated by apolipoprotein A1, which is the main protein in high-density lipoprotein - has been associated with an increased risk of cardiovascular events. CSL112 is human apolipoprotein A1 derived from plasma that increases cholesterol efflux capacity. Whether infusions of CSL112 can reduce the risk of recurrent cardiovascular events after acute myocardial infarction is unclear.Methods We conducted an international, double-blind, placebo-controlled trial involving patients with acute myocardial infarction, multivessel coronary artery disease, and additional cardiovascular risk factors. Patients were randomly assigned to receive either four weekly infusions of 6 g of CSL112 or matching placebo, with the first infusion administered within 5 days after the first medical contact for the acute myocardial infarction. The primary end point was a composite of myocardial infarction, stroke, or death from cardiovascular causes from randomization through 90 days of follow-up.Results A total of 18,219 patients were included in the trial (9112 in the CSL112 group and 9107 in the placebo group). There was no significant difference between the groups in the risk of a primary end-point event at 90 days of follow-up (439 patients [4.8%] in the CSL112 group vs. 472 patients [5.2%] in the placebo group; hazard ratio, 0.93; 95% confidence interval [CI], 0.81 to 1.05; P=0.24), at 180 days of follow-up (622 patients [6.9%] vs. 683 patients [7.6%]; hazard ratio, 0.91; 95% CI, 0.81 to 1.01), or at 365 days of follow-up (885 patients [9.8%] vs. 944 patients [10.5%]; hazard ratio, 0.93; 95% CI, 0.85 to 1.02). The percentage of patients with adverse events was similar in the two groups; a higher number of hypersensitivity events was reported in the CSL112 group.Conclusions Among patients with acute myocardial infarction, multivessel coronary artery disease, and additional cardiovascular risk factors, four weekly infusions of CSL112 did not result in a lower risk of myocardial infarction, stroke, or death from cardiovascular causes than placebo through 90 days. (Funded by CSL Behring; AEGIS-II ClinicalTrials.gov number, NCT03473223.) In patients with acute MI, multivessel coronary artery disease, and other cardiovascular risk factors, CSL112 did not reduce the risk of MI, stroke, or death from cardiovascular causes. LA - English DB - MTMT ER - TY - JOUR AU - Wang, Z. AU - Zhao, B. AU - Jia, J. TI - Gantenerumab in Early Alzheimer’s Disease JF - NEW ENGLAND JOURNAL OF MEDICINE J2 - NEW ENGL J MED VL - 390 PY - 2024 IS - 9 SP - 866 SN - 0028-4793 DO - 10.1056/NEJMc2314291 UR - https://m2.mtmt.hu/api/publication/34783162 ID - 34783162 N1 - Export Date: 11 April 2024 CODEN: NEJMA LA - English DB - MTMT ER - TY - JOUR AU - Donner, E. AU - Devinsky, O. AU - Friedman, D. TI - Wearable Digital Health Technology for Epilepsy JF - NEW ENGLAND JOURNAL OF MEDICINE J2 - NEW ENGL J MED VL - 390 PY - 2024 IS - 8 SP - 736 EP - 7445 PG - 6710 SN - 0028-4793 DO - 10.1056/NEJMra2301913 UR - https://m2.mtmt.hu/api/publication/34780211 ID - 34780211 N1 - Division of Neurology, Hospital for Sick Children, The Department of Paediatrics, University of Toronto, Toronto, Canada Epilepsy Center, Department of Neurology, New York University Grossman School of Medicine, New York, United States Cited By :1 Export Date: 10 April 2024 CODEN: NEJMA Correspondence Address: Donner, E.; Division of Neurology, 175 Elizabeth St., Canada; email: elizabeth.donner@sickkids.ca Chemicals/CAS: carbamazepine, 298-46-4, 8047-84-5 AB - This review article presents two true-life clinical vignettes that illustrate how digital health technology can aid providers caring for patients with epilepsy. Specific information that would identify real patients has been removed or altered. The vignettes are followed by a discussion of how these methods were used in the care of the patients. Copyright © 2024 Massachusetts Medical Society. LA - English DB - MTMT ER - TY - JOUR AU - Hauser, S.L. TI - Silencing Immune Dialogue in Multiple Sclerosis JF - NEW ENGLAND JOURNAL OF MEDICINE J2 - NEW ENGL J MED VL - 390 PY - 2024 IS - 7 SP - 662 EP - 663 PG - 2 SN - 0028-4793 DO - 10.1056/NEJMe2314434 UR - https://m2.mtmt.hu/api/publication/34780911 ID - 34780911 N1 - Export Date: 10 April 2024 CODEN: NEJMA Correspondence Address: Hauser, S.L.; The UCSF Weill Institute for Neurosciences, United States Chemicals/CAS: CD40 ligand, 226713-27-5; frexalimab, 2515463-86-0; gadolinium, 7440-54-2 LA - English DB - MTMT ER - TY - JOUR AU - Al-Khatib, S.M. TI - Cardiac Implantable Electronic Devices. JF - NEW ENGLAND JOURNAL OF MEDICINE J2 - NEW ENGL J MED VL - 390 PY - 2024 IS - 5 SP - 442 EP - 454 PG - 13 SN - 0028-4793 DO - 10.1056/NEJMra2308353 UR - https://m2.mtmt.hu/api/publication/34814633 ID - 34814633 N1 - Export Date: 23 April 2024 CODEN: NEJMA Correspondence Address: Al-Khatib, S.M.; Division of Cardiology and the Duke Clinical Research Institute, United States LA - English DB - MTMT ER - TY - JOUR AU - Dauleh, H. AU - Amin, R. AU - Pasha, M. AU - Hussain, K. TI - Adjuvant Alpelisib Therapy for Congenital Hyperinsulinism. JF - NEW ENGLAND JOURNAL OF MEDICINE J2 - NEW ENGL J MED VL - 390 PY - 2024 IS - 4 SP - 379 EP - 380 PG - 2 SN - 0028-4793 DO - 10.1056/NEJMc2312807 UR - https://m2.mtmt.hu/api/publication/34768780 ID - 34768780 N1 - Export Date: 4 April 2024 CODEN: NEJMA Chemicals/CAS: alpelisib, 1217486-61-7; diazoxide, 364-98-7; glucose, 50-99-7, 84778-64-3, 8027-56-3; hydrocortisone, 50-23-7; nifedipine, 21829-25-4; octreotide, 83150-76-9, 1607842-55-6, 135467-16-2, 79517-01-4; Alpelisib; Thiazoles LA - English DB - MTMT ER - TY - JOUR AU - Sonneveld, Pieter AU - Dimopoulos, Meletios A. AU - Boccadoro, Mario AU - Quach, Hang AU - Ho, P. Joy AU - Beksac, Meral AU - Hulin, Cyrille AU - Antonioli, Elisabetta AU - Leleu, Xavier AU - Mangiacavalli, Silvia AU - Perrot, Aurore AU - Cavo, Michele AU - Belotti, Angelo AU - Broijl, Annemiek AU - Gay, Francesca AU - Mina, Roberto AU - Nijhof, Inger S. AU - van de Donk, Niels W. C. J. AU - Katodritou, Eirini AU - Schjesvold, Fredrik AU - Sureda Balari, Anna AU - Rosinol, Laura AU - Delforge, Michel AU - Roeloffzen, Wilfried AU - Silzle, Tobias AU - Vangsted, Annette AU - Einsele, Hermann AU - Spencer, Andrew AU - Hajek, Roman AU - Jurczyszyn, Artur AU - Lonergan, Sarah AU - Ahmadi, Tahamtan AU - Liu, Yanfang AU - Wang, Jianping AU - Vieyra, Diego AU - van Brummelen, Emilie M. J. AU - Vanquickelberghe, Veronique AU - Sitthi-Amorn, Anna AU - de Boer, Carla J. AU - Carson, Robin AU - Rodriguez-Otero, Paula AU - Blade, Joan AU - Moreau, Philippe TI - Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma JF - NEW ENGLAND JOURNAL OF MEDICINE J2 - NEW ENGL J MED VL - 390 PY - 2024 IS - 4 SP - 301 EP - 313 PG - 12 SN - 0028-4793 DO - 10.1056/NEJMoa2312054 UR - https://m2.mtmt.hu/api/publication/34643511 ID - 34643511 N1 - Erasmus MC Cancer Institute, Rm. 822, P.O. Box 2040, CA, Rotterdam, 3000, Netherlands Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam, Netherlands Department of Hematology, St. Antonius Hospital, Nieuwegein, Netherlands University Medical Center Groningen, Groningen, Janssen Research and Development, Leiden, Netherlands National and Kapodistrian University of Athens, Athens, Greece Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece Myeloma Unit, Division of Hematology, Univ. of Turin and Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Italy Division of Hematology 1, AOU Citta della Salute e della Scienza di Torino, Italy Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy Department of Hematology, Careggi Hospital and University of Florence, Florence, Italy Division of Hematology, Fondazione Istituto di Ricovero e Cura A Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy IRCCS AOU di Bologna, Istituto di Ematologia "seragnoli" and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universita di Bologna, Bologna, Italy Department of Hematology, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, A. Belotti, Brescia, Italy University of Melbourne and St. Vincent s Hospital, Melbourne, VIC, Australia Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW, Australia Malignant Haematology and Stem Cell Transplantation Service, Alfred Health Monash University, Melbourne, VIC, Australia Ankara University, Ankara, Turkey Department of Hematology, Hopital Haut Leveque, University Hospital, Pessac, France University of Poitiers, Centre Hospitalier Universitaire (CHU) and INSERM 1313, Poitiers, France CHU de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Universite de Toulouse, Universite Paul Sabatier, Service D Hematologie, Toulouse, France Hematology Department, University Hospital Hotel-Dieu, Nantes, France Oslo Myeloma Center, Department of Hematology, Oslo University Hospital and KG Jebsen Center for B-cell Malignancies, University of Oslo, Norway Hematology Department, Institut Catala D Oncologia Hospitalet, Instituto de Investigacion Biomedica de Bellvitge, Spain University of Barcelona, Hospital Clinic de Barcelona, Institut D Investigacions Biomediques August Pi i Sunyer, Spain Grupo Espanol de Mieloma Programa Espanol de Tratamientos en Hematologia, Barcelona and the Department of Hematology, Cancer Center Clinica Universidad de Navarra, Pamplona, Spain University of Leuven, Leuven, Belgium Janssen Research and Development, Beerse, Belgium Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland Department of Hematology, Rigshospitalet, Copenhagen, Denmark Department of Internal Medicine II, University Hospital Wurzburg, Wurzburg, Germany Department of Hemato-oncology, University Hospital Ostrava, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Krakow, Poland Genmab US, PlainsboroNJ, United States Janssen Research and Development, Beijing, China Janssen Research and Development, Spring House, PA, United States Export Date: 17 March 2024 CODEN: NEJMA Correspondence Address: Sonneveld, P.; Erasmus MC Cancer Institute, Rm. 822, P.O. Box 2040, CA, Netherlands; email: p.sonneveld@erasmusmc.nl Chemicals/CAS: bortezomib, 179324-69-7, 197730-97-5, 444576-08-3; daratumumab, 945721-28-8; dexamethasone, 50-02-2; lenalidomide, 191732-72-6, 1243329-97-6, 202271-91-8, 874946-00-6 LA - English DB - MTMT ER -